RA0757

antibody from Oursmab
Targeting: TNFRSF13C BAFFR, CD268
Provider product page for RA0757
Western blot
ELISA
Immunocytochemistry
Flow cytometry
Functional assay

Antibody data

Product number
RA0757 - Provider product page
Provider
Oursmab
Product name
Ianalumab (Biosimilar Reference Antibody) (TNFRSF13C)
Antibody type
Monoclonal
Description
Ianalumab (VAY-736) is a fully human monoclonal antibody targeting the B-cell activating factor receptor (BAFF-R). It is distinguished by a novel dual mechanism of action: it combines specific blockade of BAFF-R-mediated signaling with potent, Fc-mediated antibody-dependent cellular cytotoxicity (ADCC). By binding to BAFF-R, ianalumab competitively inhibits the interaction with its natural ligand, BAFF, thereby depriving B cells of a critical survival signal. Concurrently, its engineered Fc domain strongly engages Fc¦Ã receptors on natural killer (NK) cells and macrophages, leading to the direct lysis and depletion of BAFF-R-positive B cells. This two-pronged approach aims to achieve profound and sustained suppression of pathogenic B-cell populations.
Reactivity
Human
Isotype
IgG
Vial size
100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg
Concentration
Bottled at the concentration indicated on the vial.
Storage
Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.
TNFRSF13C protein structure - RA0757 shown in red.